Weekly Healthcare Policy Round-Up

In this week’s Health Policy Round-Up, ALF shares the most up to date news happening in Washington DC.

• While the House of Representatives and Senate are still out on August recess, let’s make sure our voices are heard! By sharing your personal experiences, you help lawmakers understand that liver disease isn’t just numbers and statistics; it’s real people, families, and futures. Take action for liver patients here!

• On August 15^th, the Food and Drug Administration (FDA) granted accelerated approval for Novo Nordisk’s Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease. This new treatment option for MASH will be covered under Medicare, expanding access to more patients. FDA approval of Wegovy marks the first GLP-1 therapy approved for MASH, offering new hope to patients and their families. Learn more about the new treatment option here.